Moderna’s two-dose COVID-19 vaccine commanded public attention with the announcement of its 94.5% efficacy rate. The vaccine has yet to be approved by the FDA, but the company has applied for emergency authorization and the first doses could be distributed this year, the Washington Post reported Nov. 30. Here’s how to buy Moderna stock.
Latest updates
Tuesday, December 1: Advisors to the Center for Disease Control recommended that the first doses of any COVID-19 vaccine should be given to health-care workers and workers in nursing homes and other care facilities, according to news reports.
Monday, November 30: Moderna files for emergency authorization of its vaccine, and the Washington Post reports that 40 million dose of COVID-19 vaccines could be distributed by year’s end.
Monday, November 16: Moderna announces its vaccine is 94.5% effective based on late-stage trial data.
How to buy shares in Moderna
Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
Search for Moderna. Find the stock by name or ticker symbol: MRNA. Research its history to confirm it's a solid investment against your financial goals.
Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Moderna reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Moderna, depending on your broker.
Check in on your investment. Congratulations, you own a part of Moderna. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.
Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
Our pick for active investors. We picked Webull for this category because its platform offers features that cater to advancing investors as well as beginners. The desktop app is outfitted with an extensive set of research tools, the mobile app gets high grades from users and traders can test strategies with a paper-trading feature.
On November 16, Moderna released a statement based on late-stage trial data of its two-dose coronavirus vaccine it’s developing with the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases. It claims the vaccine is 94.5% effective in preventing COVID-19. This announcement arrived just one week behind vaccine competitor Pfizer’s 90% efficacy rate statement.
Moderna’s data comes from a study of 30,000 volunteers and was released as a news statement — not in a peer-reviewed journal. This vaccine data is promising but far from conclusive. There’s still room for Moderna’s protection rate to change by the time it finishes its study.
Moderna has now applied for emergency-use approval from the US Food and Drug Administration (FDA). The FDA requires coronavirus vaccines to hold an efficacy rate of at least 50% to be approved.
In response to Moderna’s November announcement, its stock spiked by over 8%, the Dow Jones Industrial Average rose by nearly 400 points and the S&P 500 set a record high above 3,615 points.
Moderna vs. Pfizer
Both Moderna and Pfizer have made numerous news headlines as they work to develop effective coronavirus vaccines. But how do their vaccines compare? Here’s how these COVID-19 vaccines stack up.
Moderna
Pfizer
Type of vaccine
Messenger RNA (mRNA)
Messenger RNA (mRNA
Efficacy rate
94.5%
95%
Trial size
30,000 people
43,538 people
Number of doses
2 shots, 28 days apart
2 shots, 21 days apart
Storage
-20°C
-70°C
Production
Up to 20 million doses by the end of 2020
Up to 50 million doses by the end of 2020
Years in business
10
171
Number of manufactured drugs
0
300+
Moderna share price
Use our graph to track the performance of MRNA stocks over time.
Compare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Moderna stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Moderna price performance over time
Historical closes compared with the close of $N/A from 2021-02-25
1 week (2021-02-23)
N/A
1 month (2021-02-02)
N/A
3 months (2020-12-02)
N/A
6 months (2020-09-02)
N/A
1 year (2020-03-02)
N/A
2 years (2019-03-02)
N/A
3 years (2018-03-02)
N/A
5 years (2016-03-02)
N/A
Moderna financials
Revenue TTM
USD$803.4 million
Gross profit TTM
USD$-574,877,000
Return on assets TTM
-10.69%
Return on equity TTM
-39.99%
Profit margin
-92.99%
Book value
$6.423
Market capitalisation
USD$58.7 billion
TTM: trailing 12 months
Shorting Moderna shares
There are currently 14.7 million Moderna shares held short by investors – that's known as Moderna's "short interest". This figure is 26.5% down from 20.0 million last month.
There are a few different ways that this level of interest in shorting Moderna shares can be evaluated.
Moderna's "short interest ratio" (SIR)
Moderna's "short interest ratio" (SIR) is the quantity of Moderna shares currently shorted divided by the average quantity of Moderna shares traded daily (recently around 14.8 million). Moderna's SIR currently stands at 0.99. In other words for every 100,000 Moderna shares traded daily on the market, roughly 990 shares are currently held short.
However Moderna's short interest can also be evaluated against the total number of Moderna shares, or, against the total number of tradable Moderna shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Moderna shares in existence, roughly 40 shares are currently held short) or 0.0483% of the tradable shares (for every 100,000 tradable Moderna shares, roughly 48 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moderna.
We're not expecting Moderna to pay a dividend over the next 12 months.
Moderna share price volatility
Over the last 12 months, Moderna's shares have ranged in value from as little as $19.31 up to $189.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moderna's is 1.5021. This would suggest that Moderna's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Moderna overview
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Frequently asked questions
Currently 10.005% of Moderna shares are held by insiders and 52.056% by institutions.
Latest data suggests 1,300 work at Moderna.
Moderna's fiscal year ends in December.
Moderna's address is: 200 Technology Square, Cambridge, MA, United States, 02139
Moderna's international securities identification number is: US60770K1079
Moderna's Committee on Uniform Securities Identification Procedures number is: 56804Q201
Jing Jun Ma is an innovations expert at Finder. With a decade of experience in digital marketing and programming, Jing is a tech and data guy. He wrangles data to make it useful for consumers facing a decision.
How likely would you be to recommend finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
Advertiser Disclosure
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
